Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 11/20 | 0.35 |
| ▸ | FNTB | P49356 | 11/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30477908 | 1.00 | MME (0.41) | MMEFNTAFNTBPGGT1BENPEP | |
| SCHEMBL30477916 | 1.00 | MME (0.41) | MMEFNTAFNTBPGGT1BENPEP | |
| SCHEMBL30477918 | 1.00 | MME (0.41) | MMEFNTAFNTBPGGT1BENPEP | |
| SCHEMBL30477910 | 1.00 | MME (0.41) | MMEFNTAFNTBPGGT1BENPEP | |
| SCHEMBL30477922 | 1.00 | MME (0.41) | MMEFNTAFNTBPGGT1BENPEP | |
| SCHEMBL29395252 | 0.96 | MME (0.46) | MMEFNTAFNTBPGGT1BENPEP | |
| SCHEMBL30477914 | 0.94 | FNTA (0.38) | MMEFNTAFNTBPGGT1BACE | |
| SCHEMBL30477919 | 0.94 | FNTA (0.38) | MMEFNTAFNTBPGGT1BACE | |
| SCHEMBL30477907 | 0.94 | FNTA (0.38) | MMEFNTAFNTBPGGT1BACE | |
| SCHEMBL30477913 | 0.94 | FNTA (0.38) | MMEFNTAFNTBPGGT1BACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-12390520-B2 | Vaccination in newborns and infants | Cure Vac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| US-20240390478-A1 | VACCINATION IN ELDERLY PATIENTS | CureVac SE (DE) | 2024-11-28 | — | — | US | disclosed |
| US-12036277-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-07-16 | — | — | US | disclosed |
| US-20240197857-A1 | VACCINATION WITH mRNA-CODED ANTIGENS | CureVac SE (DE) | 2024-06-20 | — | — | US | disclosed |
| US-11975064-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-05-07 | — | — | US | disclosed |
| US-20230285594-A1 | COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION | CureVac SE (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230233662-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2023-07-27 | — | — | US | disclosed |
| US-11672856-B2 | Vaccination in newborns and infants | CureVac SE (DE) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | HLA-DRB1, TLR3, TLR9 | MME 2664/4885FNTA 2481/4885FNTB 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.